StreetInsider.com News Articles

Acadia Pharmaceuticals (ACAD) PT Raised to $36 at BMO Capital

Tue, 21 Jul 2026 07:36:53 -0400

BMO Capital analyst Evan David Seigerman raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $36.00 (from $34.00) while maintaining a Outperform rating.

Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel

Mon, 20 Jul 2026 16:25:31 -0400

Stifel analyst Paul Matteis raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $25.00 (from $24.00) while maintaining a Hold rating.

The analyst comments "We’re reiterating our Hold rating on ACAD following our deep dive on remlifanserin, their next-gen 5-HT2A inverse agonist currently in development for ADP and LBDP. Bottom line: while we think ACAD has given remlifanserin the best chance at success with a well designed and well powered ph2 study, we are unsure if this is enough to overcome what we believe is a very safe, but only modestly effective antipsychotic mechanism in 5HT2a inverse agonism (i.e. antagonism).

Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel

Mon, 20 Jul 2026 16:25:31 -0400

Stifel analyst Paul Matteis raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $25.00 (from $24.00) while maintaining a Hold rating.

Mizuho n Acadia Pharmaceuticals (ACAD): 'we view risk/reward as skewed significantly to the upside'

Mon, 20 Jul 2026 12:25:56 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "This morning, Acadia announced that the RADIANT Phase 2 trial of remlifanserin in Alzheimer's psychosis completed enrollment, largely in-line with the company's 1H26 timeline. Recall that the pace of the Phase 2 enrollment was set by Acadia's efforts to ensure inclusion of appropriate patients with biomarker-confirmed (amyloid plaque deposition) Alzheimer's disease. With completion of enrollment, management now has greater visibility into the topline data timeline and narrowed their guidance from AugustOctober to September-October, 2026. At current levels, we view risk/reward as

FDA grants fast track status to Acadia drug for Alzheimer's psychosis

Mon, 20 Jul 2026 09:05:12 -0400

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced that the U.S. Food and Drug Administration has granted Fast Track designation to remlifanserin, an investigational 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.

Fast Track designation is intended to facilitate development and expedite FDA review of drugs targeting serious conditions with unmet medical needs. There are currently no FDA-approved therapies for Alzheimer's disease psychosis.

"FDA Fast Track designation for remlifanserin underscores the significant unmet need for new treatment options for people living with Alzheimer's disease psychosis, a serious condition for which there are currently no FDA-approved therapies,"

FDA grants fast track status to Acadia drug for Alzheimer's psychosis

Mon, 20 Jul 2026 09:05:12 -0400

FDA grants fast track status to Acadia drug for Alzheimer's psychosis

Mon, 20 Jul 2026 09:05:12 -0400

FDA grants fast track status to Acadia drug for Alzheimer's psychosis

Mon, 20 Jul 2026 09:05:12 -0400

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

Mon, 20 Jul 2026 09:05:00 -0400

-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies